Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESULT: Liprotamase vs Porcine PERT in CF-EPI
NCT03051490Phase 3Unknown
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Apr 2017
- Primary completion
- Feb 2018
- Modality
- Replacement Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of liprotamase in exocrine pancreatic insufficiency (EPI) (2 arms), sponsored by Anthera Pharmaceuticals, Inc. Primary endpoint: Coefficient of Fat Absorption at 8 weeks. Status: unknown.
02
Drugs
liprotamase
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT03051490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051490.